What are Yamanaka factors?
The Yamanaka factors are four genes: Oct4, Sox2, Klf4, and c-Myc, often shortened to OSKM. Switch all four on inside an ordinary adult cell, a skin cell, say, and something that should be impossible happens. The cell forgets what it is. It winds back through its own developmental history and becomes a stem cell capable of turning into any tissue in the body.
Before 2006, biology held that development ran one way. A cell became a skin cell and stayed a skin cell; the only route to a pluripotent cell was through an embryo. Shinya Yamanaka's laboratory broke that rule, first in mouse cells in 2006, then in adult human cells in 2007, and won the Nobel Prize for it in 2012. The cells that come out are called induced pluripotent stem cells, or iPSCs.
For regenerative medicine, this is the closest thing the field has to a foundational discovery. Every conversation about reprogramming, epigenetic age, and cellular rejuvenation traces back to those four genes.
How does it work?
Every cell in your body carries the same DNA. What makes a liver cell different from a neuron is not the genes it has but which genes are switched on, a pattern written in chemical marks sitting on top of the DNA. That layer is the epigenome, and it is where a cell's identity and, it turns out, much of its age are recorded.
The Yamanaka factors are master switches. Oct4 and Sox2 are the core machinery of embryonic identity; Klf4 and c-Myc help clear the path and drive the cell through it. Together they overwrite the epigenetic pattern, erasing the marks that say "skin cell" along with the marks accumulated over decades of living. The DNA sequence never changes. The instructions on top of it are rewritten.
That is the detail that turned a stem cell technique into a longevity idea: reprogramming resets biological age markers along with cell identity. The cell does not just forget its job. It forgets how old it is.
Why they matter in regenerative medicine
Three doors opened at once.
The first is unlimited patient-matched cells. Take a skin sample, reprogram it, and grow heart muscle, dopamine neurons, or retinal cells that share the donor's DNA. That is what the clinical trials below are testing, and it sidesteps the ethical and supply problems of embryonic cells entirely.
The second is disease modeling: reprogram cells from someone with a genetic condition, grow the affected tissue in a dish, and study the disease in human cells instead of a mouse approximation.
The third is the one that changed longevity science. If four genes can reset a cell's age markers, aging looks less like irreversible wear and more like accumulated changes in a system that can, in principle, be edited. That reframing launched an entire industry, and it is covered in our companion article on partial reprogramming.
The catch: full reprogramming erases the cell
Full reprogramming is a blunt instrument. A cell taken all the way back to pluripotency has lost the identity that made it useful. Do that inside a living body and you do not get a rejuvenated organ, you get tissue that has forgotten its job, and pluripotent cells left in a living animal can form teratomas, the disorganized tumors that are the hallmark risk of the pluripotent state.
This is why the field split. One branch does reprogramming in the laboratory, under controlled conditions, then differentiates the resulting stem cells into the specific tissue needed and transplants that, never the pluripotent cells themselves. The other branch, partial reprogramming, applies the factors briefly, hoping to reset age markers without erasing identity. Both branches are live, and the safety question is the reason they exist.
Small molecules: reprogramming without gene delivery
The original method delivered the four genes with viruses, which is powerful and unsuited to routine human medicine: viral delivery can insert genes permanently, and c-Myc is a known cancer gene. So researchers asked whether chemistry could do the same job.
It can. Chemical reprogramming uses cocktails of small molecules, drug-like compounds rather than genes, to push cells through the same transition, and the field has advanced to human cells. In 2025, a study in EMBO Molecular Medicine reported that chemical reprogramming improved cellular hallmarks of aging and extended lifespan in a model organism, taking the small-molecule approach directly at the aging question.
Why this matters practically: molecules can be dosed, timed, and stopped in ways genes cannot, and they leave no permanent genetic footprint. If cellular rejuvenation ever reaches everyday medicine, most researchers expect it to arrive as chemistry rather than gene therapy.
The SSEA-3 connection
Here is where the reprogramming story meets the cells we write about elsewhere in this library. A rare population inside ordinary adult tissue naturally expresses pluripotency markers, including the surface marker SSEA-3, without being reprogrammed by anyone. These are the stress-enduring cells covered in our SSEA-3 positive stem cell article, first described in 2010.
What makes them relevant here is the contrast. Laboratory reprogramming produces pluripotent cells that carry teratoma risk; these naturally occurring cells express pluripotency-associated genes and did not form teratomas in the foundational work. Research has examined how their pluripotency gene expression is held in check, including regulation by the tumor-suppressor let-7 family, and separate work describes their immune-privilege behavior.
The honest framing: nature appears to run a restrained version of the program the reprogramming labs are building deliberately. That is a genuinely interesting parallel, and it is not a claim that these cells rejuvenate tissue in humans. The evidence for what they do clinically sits in their own article.
What people should know in practice
Nobody is receiving Yamanaka factors as a treatment today. Where reprogramming has reached patients, it is through the laboratory route: cells reprogrammed and differentiated under manufacturing conditions, then transplanted as finished tissue in registered trials. That distinction gets blurred constantly in marketing, and it is worth holding firmly.
If a clinic offers you "reprogramming therapy" or "Yamanaka factor treatment," the correct response is skepticism and specific questions: what exactly is being administered, made how, tested how, and in which trial has it been studied? The real work in this field is meticulous, slow, and registered, which is exactly what the next section covers.
The pros and the cons
What's promising
- A Nobel-recognized discovery that rewrote what biologists thought cells could do.
- Patient-matched cells of any tissue type, without embryos.
- Reprogramming resets biological age markers, not just cell identity.
- Real clinical trials now running with iPSC-derived tissue in Parkinson's disease and heart failure.
What's uncertain
- Pluripotent cells carry teratoma risk, which governs every safety protocol in the field.
- c-Myc is an oncogene, one reason non-viral and chemical methods are pursued.
- Full reprogramming destroys cell identity, so it cannot be used directly in a living body.
- Trials are early phase; no iPSC-derived therapy is approved for routine use.
Worth considering
- Nothing sold to consumers today delivers Yamanaka factors; treat such claims as a red flag.
- Laboratory reprogramming plus differentiation is the route that reached patients.
- Chemical reprogramming is the direction to watch for eventual everyday medicine.
- Any cell therapy decision belongs with a qualified physician and a registered protocol.
What the key studies tested
Our framing rule for evidence: a study tests one method, in one system, on one endpoint. Where the evidence sits:
Preclinical & practice
Chemical reprogramming, in vivo reprogramming, and all rejuvenation work.
Early trials
iPSC-derived dopamine progenitors in Parkinson's; iPSC-derived cardiomyocytes in heart failure.
Late-stage trials
None yet for any iPSC-derived therapy.
Approved uses
None. The technique's established value today is research and manufacturing.
And the studies that anchor the story:
- Takahashi and Yamanaka, Cell 2006: four factors turned mouse fibroblasts into pluripotent stem cells. The paper that broke the one-way rule.
- Takahashi et al., Cell 2007: the same four factors worked on adult human fibroblasts, which is what made the discovery medically relevant.
- The Kyoto trial: allogeneic iPSC-derived dopamine progenitors transplanted in Parkinson's disease, with a 2025 report on current status, plus preclinical biodistribution and safety work supporting programs of this kind.
- Nature Medicine 2026: an early-stage randomized trial of allogeneic iPSC-derived cardiomyocytes injected into the heart muscle in advanced ischemic heart failure. Registered iPSC cardiac programs are also underway (for example NCT04945018).
- EMBO Molecular Medicine 2025: chemical reprogramming improved hallmarks of aging and extended lifespan, moving small-molecule methods toward the aging question directly.
Every study behind this article is filterable in our research library on the Science page.
Questions people ask
Can Yamanaka factors reverse aging in a person?
Not today, and not in the form the headlines suggest. The factors reset age markers in cells, which is real and important, and full reprogramming also erases cell identity and carries tumor risk, so it cannot simply be applied to a living body. The approaches aiming at rejuvenation use brief, partial exposure and remain preclinical; nothing is approved or available as treatment.
What is the difference between iPSCs and embryonic stem cells?
Origin, mostly. Embryonic stem cells come from an embryo; iPSCs are made by reprogramming an adult cell with the Yamanaka factors, so they can be patient-matched and carry none of the embryo-related ethical issues. Both are pluripotent, and both share the teratoma risk that comes with the pluripotent state, which is why therapies differentiate them into finished tissue before transplant.
Has anyone been treated with iPSC-derived cells?
Yes, in registered early-phase trials rather than routine care. iPSC-derived dopamine progenitors have been transplanted in Parkinson's disease, and an early-stage randomized trial has injected iPSC-derived heart muscle cells in advanced heart failure. These are first-in-human scale studies; no iPSC-derived therapy is approved for general use anywhere.
What are small-molecule Yamanaka factors?
Cocktails of drug-like chemicals that push cells through the same reprogramming transition without delivering genes. The appeal is control and safety: molecules can be dosed and stopped, and they leave no permanent genetic change. Chemical reprogramming now works in human cells and has been used in aging research, and it remains laboratory work rather than medicine.
What to take away
If you remember five things from this article, make them these:
- Four genes, OSKM, can return an adult cell to a stem-cell state, a Nobel-winning discovery that rewrote developmental biology.
- Reprogramming rewrites the epigenetic layer, which is why it resets cell identity and biological age markers together.
- Full reprogramming erases what a cell is and carries teratoma risk, which is why therapies reprogram in the lab and transplant finished tissue.
- Small-molecule chemical reprogramming is the safer-by-design direction, and it is laboratory-stage.
- Nothing available to consumers delivers Yamanaka factors; the real work is in registered early-phase trials.
The evidence
Selected references, each verified against primary sources (PubMed and ClinicalTrials.gov). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Reprogramming is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.